![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves 23andMe’s Home Breast Cancer Testing
FDA Approves 23andMe’s Home Breast Cancer Testing
![Purple_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Purple_Approved_Stamp.gif?t=1576639773&width=430)
March 8, 2018
The FDA approved 23andMe’s at-home screenings for three breast cancer mutations.
Women who carry one of the three BRCA1 and BRCA2 gene mutations are at substantially increased risk for developing breast and ovarian cancer.
The genetic testing company will report the test results as part of its Health and Ancestry product.
Related Events
Upcoming Events
-
21Oct